http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102239291-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102239291-B1 |
| titleOfInvention | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof |
| abstract | The present invention is a granule containing tadalafil or a pharmaceutically acceptable salt thereof as an active ingredient; Granules of specific particle size and density produced through wet processing; At least one disintegrant selected from the group consisting of sodium starch glycolate, calcium carboxymethylcellulose, starch, alginic acid, and sodium alginate; And it provides a tadalafil chewable tablet comprising a pharmaceutically acceptable additive. The chewable tablet of tadalafil of the present invention not only has excellent dissolution rate of tadalafil, has a low sense of foreign body in the oral cavity, has no discomfort even if it is disintegrated in the oral cavity with an improved taste and aroma, and can be chewed without water, so it is difficult to swallow in the oral cavity. As a drug that has improved adherence to patients who do not have the disease, it may exhibit improved efficacy of a PDE-5 inhibitor, and thus may be usefully used in the treatment of patients with erectile dysfunction and pulmonary arterial hypertension. |
| priorityDate | 2013-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.